6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections

Pharmacotherapy of Infective Endocarditis and CIED Infections

Infective endocarditis (IE) represents a severe, life-threatening endovascular infection characterized by colonization of the endocardial surface of the heart, most commonly the heart valves. The pharmacotherapeutic management of IE requires an understanding of endovascular biofilm dynamics, high bacterial inocula ($10^9$ to $10^{10}\text{ CFU/g}$ of vegetation tissue), and the necessity of prolonged, bactericidal antimicrobial regimens. The American Heart Association (AHA), Infectious Diseases Society of America (IDSA), and European Society of Cardiology (ESC) consensus guidelines provide evidence-based frameworks to guide definitive pharmacotherapy across distinct microbiological and host subsets.

---

Diagnostic Criteria and Clinical Assessment

Clinical suspicion of infective endocarditis requires rapid, systematic evaluation utilizing the Modified Duke Criteria, updated in 2023 by the International Society for Cardiovascular Infectious Diseases (Duke-ISCVID Criteria). The diagnosis is classified as Definite, Possible, or Rejected based on pathological, microbiological, and clinical-imaging criteria.

Duke-ISCVID Diagnostic Criteria Framework

Major vs. Minor Criteria Breakdown

                    ┌──────────────────────────────────────────────┐
                    │       DUKE-ISCVID CRITERIA ASSESSMENT        │
                    └──────────────────────┬───────────────────────┘
                                           │
                ┌──────────────────────────┴──────────────────────────┐
                ▼                                                     ▼
    MAJOR CRITERIA                                        MINOR CRITERIA
    1. Blood Cultures:                                    1. Predisposition: Prosthetic valve,
       - Typical IE organisms in >=2 cultures             prior IE, congenital heart disease, IVDU
       - Persistent bacteremia (>12h apart)               2. Fever: Temp >= 38.0°C (100.4°F)
       - Single positive Coxiella burnetii culture        3. Vascular: Arterial emboli, septic
         or Phase I IgG titer > 1:800                     pulmonary infarcts, Janeway lesions,
    2. Imaging Evidence:                                  mycotic aneurysm, intracranial hemorrhage
       - Echocardiogram (TTE/TEE): Vegetation,            4. Immunologic: Glomerulonephritis,
         abscess, pseudoaneurysm, new dehiscence          Osler nodes, Roth spots, Rheumatoid factor
       - Cardiac CT: Perivalvular lesions                 5. Microbiological: Positive culture not
       - 18F-FDG PET/CT: Abnormal perivalvular            meeting major criteria, or serology
         activity (PVE implanted > 3 months)             indicating active infection

Diagnostic Modalities: TTE vs. TEE and Advanced Imaging

• Transthoracic Echocardiography (TTE): Rapid and noninvasive; recommended as the initial imaging modality. Sensitivity is moderate (50% to 60%) in native valves and poor in prosthetic valves or patients with obesity, chronic obstructive pulmonary disease, or chest wall deformities. A negative TTE never rules out IE when clinical suspicion is intermediate or high.
• Transesophageal Echocardiography (TEE): Demonstrates superior sensitivity (>90% to 95%) and specificity. Mandatory for: all patients with prosthetic heart valves, intracardiac devices, suspected paravalvular complications (e.g., aortic root abscess, new atrioventricular block), suboptimal TTE acoustic windows, or persistent Staphylococcus aureus bacteremia.
• Ancillary Imaging (2023 Duke-ISCVID updates): Electrocardiogram-gated Cardiac Computed Tomography (Cardiac CT) detects paravalvular complications (pseudoaneurysms, abscesses) with spatial resolution superior to TEE. Positron emission tomography with 18F-fluorodeoxyglucose ($^{18}\text{F-FDG PET/CT}$) is particularly sensitive for prosthetic valve endocarditis (PVE) implanted for $>3$ months, identifying metabolic perivalvular inflammation.

---

Pathophysiology: Native Valve vs. Prosthetic Valve Endocarditis

Native Valve Endocarditis (NVE)

Endothelial injury (caused by turbulent blood flow, valvular sclerosis, or rheumatic disease) exposes subendothelial collagen, triggering platelet and fibrin deposition to create a sterile nonbacterial thrombotic endocarditis (NBTE). During transient bacteremia (e.g., from dental procedures, cutaneous microtrauma, or genitourinary manipulation), circulating organisms adhere to the NBTE nidus via surface adhesins (microbial surface components recognizing adhesive matrix molecules, MSCRAMMs). Once adhered, bacteria replicate rapidly and stimulate further platelet-fibrin aggregation, generating an avascular, multi-layered vegetation that protects microorganisms from circulating phagocytes and complement.

Prosthetic Valve Endocarditis (PVE)

PVE accounts for 20% of all IE cases and is stratified by postoperative onset:

• Early PVE (<2 months post-implantation): Reflects intraoperative perioperative contamination. Dominated by healthcare-associated organisms: coagulase-negative staphylococci (Staphylococcus epidermidis, often methicillin-resistant), S. aureus, aerobic Gram-negative bacilli, and Candida species.
• Intermediate PVE (2 to 12 months post-implantation): Mix of nosocomial and community-acquired pathogens.
• Late PVE (>12 months post-implantation): Pathogen distribution resembles NVE, dominated by community-acquired viridans group streptococci, S. aureus, and enterococci.

PVE carries a markedly elevated risk of invasive annular ring abscesses, valve dehiscence, valve obstruction, and heart failure compared to NVE. Treatment requires extended durations ($\ge 6$ weeks) and multi-agent biofilm-active regimens.

---

Comprehensive Microbiology and Pathogen-Directed Pharmacotherapy

Overview of Regimens

---

Deep-Dive Pharmacotherapy by Organism

1. Viridans Group Streptococci and Streptococcus gallolyticus

Viridans group streptococci (VGS; including S. mitis, S. oralis, S. mutans, S. salivarius, and S. anginosus groups) and Streptococcus gallolyticus (formerly S. bovis) are frequent causes of subacute native valve endocarditis.

• Susceptible Isolates (MIC $\le 0.12\text{ mcg/mL}$): Standard therapy is Penicillin G (12–18 million units IV continuous infusion or divided every 4 hours) or Ceftriaxone (2 g IV every 24 hours) for 4 weeks. In patients with severe beta-lactam anaphylaxis, Vancomycin (15–20 mg/kg IV every 8 to 12 hours, target AUC 400–600 mg·h/L) is administered for 4 weeks.
• The 2-Week Short Course: Uncomplicated native valve VGS endocarditis in patients with normal renal function ($\text{CrCl} > 30\text{ mL/min}$) can be treated with a 2-week regimen combining Ceftriaxone 2 g IV daily PLUS Gentamicin 3 mg/kg IV daily (single daily dose). This regimen is contraindicated in patients with impaired renal function, eighth cranial nerve impairment, cardiac abscess, or prosthetic valves.
• Streptococcus gallolyticus Mandate: Isolation of S. gallolyticus requires a colonoscopy during or immediately following treatment, due to an established association with occult colorectal adenomas and adenocarcinoma (found in up to 60% of patients).

2. Staphylococcal Endocarditis (S. aureus and Coagulase-Negative Staphylococci)

Staphylococcus aureus is the leading cause of infective endocarditis globally, producing acute, necrotizing valvular destruction, large friable vegetations, and high embolic potential.

Native Valve Endocarditis (NVE) Regimens

• Methicillin-Susceptible S. aureus (MSSA):
  • Cefazolin 2 g IV every 8 hours OR Nafcillin / Oxacillin 2 g IV every 4 hours for 6 weeks.
  • Clinical Debate: While nafcillin and oxacillin have historically been standard of care, modern observational and meta-analytic evidence indicates that cefazolin provides equivalent clinical cure rates with significantly lower rates of adverse events, including acute interstitial nephritis (AIN), hypokalemia, drug-induced hepatitis, and treatment discontinuation. In patients with severe, high-inoculum MSSA endocarditis, consideration should be given to the cefazolin inoculum effect (CIE)—in which type A $\beta$-lactamase hydrolyzes cefazolin at high inocula ($10^7\text{ CFU/mL}$), elevating the MIC to $\ge 16\text{ mcg/mL}$. Where CIE is a concern, nafcillin/oxacillin or cefazolin combined with low-dose ertapenem may be utilized.
• Methicillin-Resistant S. aureus (MRSA):
  • Vancomycin 15–20 mg/kg IV every 8 to 12 hours (dosed to achieve an $AUC_{24}/MIC$ ratio of 400–600 by Bayesian estimation) OR Daptomycin 8–10 mg/kg IV once daily for 6 weeks.
  • Daptomycin is preferred when the vancomycin MIC is $>1\text{ mcg/mL}$ (vancomycin "MIC creep") or when nephrotoxicity risk is elevated. Monitor baseline and weekly creatine phosphokinase (CPK) levels for daptomycin-induced myopathy and rhabdomyolysis.

Prosthetic Valve Endocarditis (PVE) Regimens: Mandatory Triple Therapy

Unlike NVE, staphylococcal prosthetic valve endocarditis involves microbial adherence to abiotic foreign material, producing dense, multi-layered slime and polysaccharide biofilms that are impervious to cell-wall active agents alone. Therefore, staphylococcal PVE requires triple therapy for $\ge 6$ weeks:

$\text{Triple Therapy} = \text{Backbone Agent (6+ wk)} + \text{Rifampin (6+ wk)} + \text{Gentamicin (initial 2 wk)}$

1. Cell-Wall Backbone:
   • MSSA: Cefazolin 2 g IV q8h OR Nafcillin 2 g IV q4h for $\ge 6$ weeks.
   • MRSA / CoNS: Vancomycin IV (AUC 400–600) for $\ge 6$ weeks.
2. Rifampin: 300 mg PO/IV every 8 hours (or 450–600 mg PO/IV every 12 hours) for $\ge 6$ weeks. Rifampin exhibits activity against slow-growing, stationary-phase staphylococci embedded in foreign-body biofilms.
3. Gentamicin: 1 mg/kg IV every 8 hours (adjusted for renal function; target peak 3–4 mcg/mL, trough $<1\text{ mcg/mL}$) for the first 2 weeks only, providing initial bactericidal synergy to debulk the high microbial burden.

3. Enterococcal Endocarditis (Enterococcus faecalis and Enterococcus faecium)

Enterococci possess intrinsic tolerance to $\beta$-lactam and glycopeptide monotherapy: these agents inhibit cell wall synthesis bacteriostatically but do not reliably induce bacterial lysis. Eradication of endocardial vegetations requires bactericidal synergy.

Ampicillin Plus Ceftriaxone: Dual $\beta$-Lactam Synergy

Historically, the gold-standard regimen for Enterococcus faecalis IE was Ampicillin PLUS Gentamicin for 4 to 6 weeks. However, aminoglycoside therapy in enterococcal IE produces acute kidney injury in 25% to 35% of patients.

• Mechanism of Dual $\beta$-Lactam Synergy: Enterococcal cell wall synthesis depends on five penicillin-binding proteins (PBPs). Ampicillin binds with high affinity to PBP4 and PBP5, but leaves PBP2 and PBP3 partially functional. Ceftriaxone exhibits selective, high-affinity saturation of PBP2 and PBP3. When combined, ampicillin and ceftriaxone completely saturate all essential enterococcal PBPs, producing synergistic cell wall lysis identical to $\beta$-lactam/aminoglycoside combinations.
• Clinical Regimen: Ampicillin 2 g IV every 4 hours PLUS Ceftriaxone 2 g IV every 12 hours for 6 weeks.
• Clinical Trial Evidence: Multicenter prospective studies demonstrate that ampicillin plus ceftriaxone achieves clinical cure and mortality rates non-inferior to ampicillin plus gentamicin, with zero treatment-limiting nephrotoxicity. It is now the preferred first-line regimen for E. faecalis NVE and PVE, especially in patients with baseline renal impairment or advanced age.

Vancomycin-Resistant Enterococci (VRE)

Invasive endocarditis caused by vancomycin-resistant Enterococcus faecium carries a 30-day mortality approaching 40%.

• High-Dose Daptomycin Combination Therapy: Standard daptomycin doses (6 mg/kg/day) are associated with clinical failure and rapid emergence of daptomycin resistance via liaFSR mutations. Regimens require high-dose Daptomycin (10–12 mg/kg/day IV) combined with a synergistic $\beta$-lactam: Ceftaroline 600 mg IV every 8 hours, Ampicillin 2 g IV every 4 hours, or Ertapenem 1 g IV daily. The addition of a $\beta$-lactam alters bacterial cell membrane surface charge (the "see-saw phenomenon"), enhancing daptomycin binding and bacterial killing.
• Linezolid Alternative: Linezolid 600 mg PO/IV every 12 hours for $\ge 6$ weeks is an alternative, but acts bacteriostatically and is limited by cumulative bone marrow toxicity (severe thrombocytopenia and anemia developing after 2 weeks of therapy) and peripheral neuropathy.

4. HACEK Group Endocarditis

The HACEK group comprises fastidious, slow-growing Gram-negative bacilli that colonize the human oral cavity:

• Haemophilus species (H. parainfluenzae, H. aphrophilus)
• Aggregatibacter (A. actinomycetemcomitans)
• Cardiobacterium hominis
• Eikenella corrodens
• Kingella kingae

Due to plasmid-mediated $\beta$-lactamase production, ampicillin monotherapy is obsolete. The preferred first-line regimen is Ceftriaxone 2 g IV every 24 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve). Acceptable alternatives include Ampicillin-sulbactam (3 g IV every 6 hours) or a fluoroquinolone (Ciprofloxacin 500 mg PO/400 mg IV every 12 hours or Levofloxacin 500 mg IV/PO daily).

5. Blood Culture-Negative Endocarditis (BCNE)

Blood culture-negative endocarditis accounts for 5% to 10% of IE cases. The most common etiology is prior administration of antibacterial therapy before blood cultures are drawn. In patients without prior antimicrobial exposure, fastidious, intracellular, or zoonotic pathogens predominate:

• Coxiella burnetii (Q Fever): Zoonotic transmission via infected livestock placenta, milk, or dust. Diagnosed via phase I IgG titers $\ge 1:800$. Regimen: Doxycycline 100 mg PO BID PLUS Hydroxychloroquine 200 mg PO TID for 18 to 24 months. Hydroxychloroquine alkalinizes the host macrophage phagolysosome, decreasing the minimum bactericidal concentration (MBC) of doxycycline against C. burnetii. Target serum hydroxychloroquine levels: $0.8–1.2\text{ mcg/mL}$; monitor retinal toxicity every 6 months.
• Bartonella Species (B. henselae, B. quintana): Associated with cat scratches and body lice in homelessness. Regimen: Ceftriaxone 2 g IV daily PLUS Doxycycline 100 mg PO/IV BID for 6 weeks, supplemented with Gentamicin 1 mg/kg IV q8h for the initial 2 weeks.
• Tropheryma whipplei (Whipple's Disease): Indolent, culture-negative valvular destruction. Regimen: Induction with Ceftriaxone 2 g IV daily for 2 to 4 weeks, followed by maintenance with Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 DS tablet PO BID for 1 to 2 years.

---

Cardiovascular Implantable Electronic Device (CIED) Infections

CIED infections encompass permanent pacemakers (PPM), implantable cardioverter-defibrillators (ICD), and cardiac resynchronization therapy (CRT) systems.

Clinical Distinction: Pocket vs. Lead-Associated IE

                                CIED INFECTION
                                      │
           ┌──────────────────────────┴──────────────────────────┐
           ▼                                                     ▼
    POCKET INFECTION                                  LEAD-ASSOCIATED IE
    - Erythema, pain, fluctuance,                     - Systemic bacteremia, fevers, chills
      skin erosion at generator                       - Echocardiographic vegetations on leads
    - Confined to subcutaneous pocket                   or tricuspid / pulmonary valve
    - Blood cultures usually negative                 - Blood cultures positive (staphylococci)
    - Hardware extraction: MANDATORY                  - Hardware extraction: MANDATORY
    - Post-extraction antibiotics: 10-14 days         - Post-extraction antibiotics: 2-4+ weeks

The Complete Hardware Extraction Mandate

In all established CIED infections (both pocket infections and lead endocarditis), complete removal of the entire hardware system—including the pulse generator and all transvenous leads—is mandatory. Staphylococci (S. epidermidis and S. aureus) produce biofilm across the entire intravascular lead surface. Medical therapy alone without lead extraction is associated with a relapse rate $>50\%$ and a 3-fold increase in 1-year mortality.

Antimicrobial Duration and Reimplantation Protocol

1. Duration Following Complete Hardware Extraction:
   • Isolated Pocket Infection (Blood cultures negative): 10 to 14 days of targeted parenteral or oral therapy after extraction.
   • Lead Endocarditis or Bacteremia: Minimum of 2 to 4 weeks of IV targeted therapy after extraction (2 weeks for uncomplicated bacteremia clearing within 24 hours of extraction; 4 to 6 weeks for complicated bacteremia, persistent fever, valve vegetations, or septic pulmonary emboli).
2. Device Reimplantation Strategy: Re-evaluate the clinical indication for CIED support; up to 30% of patients no longer meet indications. If still required, reimplantation must be delayed until blood cultures are negative for $\ge 72\text{ hours}$ (pocket infection) or $\ge 14\text{ days}$ (valvular IE), and must be placed at a contralateral anatomical site (or via subcutaneous/leadless systems).

---

Suppurative Thrombophlebitis and Lemierre Syndrome

Lemierre Syndrome (Human Necrobacillosis)

Lemierre syndrome is a severe form of septic thrombophlebitis characterized by acute oropharyngeal infection complicated by internal jugular vein (IJV) thrombosis and metastatic septic emboli.

• Microbiology: Fusobacterium necrophorum, an anaerobic, pleomorphic Gram-negative bacillus producing hemagglutinins and lipopolysaccharide endotoxins that induce platelet aggregation and local tissue invasion.
• Pathogenesis: Primary pharyngitis or peritonsillar abscess invades the lateral pharyngeal space, causing suppurative septic thrombophlebitis of the internal jugular vein. Fragments of the infected thrombus embolize systemically, producing bilateral cavitary pulmonary nodules, empyema, and septic arthritis.
• Pharmacotherapy: High-dose Ampicillin-sulbactam (3 g IV every 6 hours), Meropenem (1 g IV every 8 hours), or Ceftriaxone (2 g IV every 24 hours) PLUS Metronidazole (500 mg IV/PO every 8 hours) for 3 to 6 weeks until clinical resolution and radiographic regression of pulmonary and venous lesions.
• Anticoagulation: Highly controversial. Anticoagulation is generally reserved for patients with retrograde thrombus progression into the intracranial dural venous sinuses or persistent bacteremia despite appropriate antibiotic therapy.

Suppurative Peripheral Thrombophlebitis

Often associated with indwelling peripheral or central venous catheters. Manifests with localized erythema, tenderness, induration, and purulence tracking along the vein course. Treatment requires immediate catheter removal, surgical vein excision if fluctuance or purulent thrombophlebitis persists, and 2 to 4 weeks of targeted IV antistaphylococcal therapy.